QC
NAGE icon

Quadrature Capital’s Niagen Bioscience NAGE Stock Holding History

Quadrature Capital’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.3K Buy
+25,795
New +$105K ﹤0.01% 1485
2026
Q1 		– Sell
-16,367
Closed -$104K – 1975
2025
Q4 		$104K Buy
+16,367
New +$114K ﹤0.01% 1096
2025
Q2 		– Sell
-30,905
Closed -$213K – 1606
2025
Q1 		$213K Buy
+30,905
New +$194K ﹤0.01% 843

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quadrature Capital's NAGE Position: Q2 2026 in Review

Quadrature Capital opened a new position in Niagen Bioscience (NAGE) in Q2 2026: 25,795 shares worth $82.3K. The stake represents ﹤0.01% of the portfolio and ranks #1485 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in NAGE as recently as Q4 2025.

Quadrature Capital first reported a position in NAGE in Q1 2025 and has held it in 3 quarters since. The position peaked at $213K in Q1 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Quadrature Capital held 25,795 shares of Niagen Bioscience worth $82.3K as of Q2 2026.
  • Niagen Bioscience was a new Quadrature Capital position in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1485 holding.
  • Quadrature Capital first reported a position in Niagen Bioscience in Q1 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Niagen Bioscience position peaked at $213K in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.